MK-677 Results: Week-by-Week Timeline

MK-677 (ibutamoren) is an oral growth hormone secretagogue — not a peptide, not an injection, and not exogenous GH. It mimics ghrelin to stimulate your pituitary to release its own growth hormone. That distinction matters for setting timeline expectations: MK-677 works through your body's natural signaling, which means effects build gradually rather than appearing overnight.

The good news is MK-677 has more human clinical data than most compounds in the GH peptide space. The 2-year Nass study, the Copinschi sleep trial, and Murphy's nitrogen balance work give us real timepoints — not just community anecdotes. This timeline synthesizes both.

This is not medical advice. MK-677 is not FDA-approved for any indication and is sold as a research chemical.

Week 1: Appetite and Sleep Come First

The earliest MK-677 effects are also its most reliable. Within 1-5 days of starting 10-25 mg before bed, two things happen:

Appetite increase. This is not a side effect — it is MK-677's primary pharmacological action as a ghrelin mimetic. Over 80% of users report noticeably increased hunger within the first few days. Chapman et al. (1996) documented this as a direct consequence of ghrelin receptor (GHS-R1a) activation (PMID 8954023). Bedtime dosing helps — you sleep through the peak hunger window.

Improved sleep. Copinschi et al. (1997) measured this objectively with polysomnography: MK-677 increased Stage IV deep sleep by approximately 50% and REM sleep by over 20% in young subjects. Older adults showed a nearly 50% increase in REM sleep and faster REM onset (PMID 9349662). Many users report noticing deeper, more restorative sleep within the first 3-5 nights.

Behind the scenes. GH pulses increase within hours of the first dose. Copinschi et al. (1996) showed that 7 days of MK-677 at 25 mg increased GH pulse frequency and raised IGF-1 levels in a dose-dependent manner in young men (PMID 8768828). You will not feel this directly, but it sets the stage for everything that follows.

What you will not see yet: Body composition changes, strength gains, or recovery improvements. Those require weeks to months of sustained GH/IGF-1 elevation.

Weeks 2-4: Water Retention, Recovery, and IGF-1 Stabilization

This is the phase where MK-677 starts showing visible changes — though not always the ones you want.

Water retention. GH elevation causes sodium and fluid retention. Most users gain 2-5 lbs of water weight in weeks 2-3, often with mild facial puffiness, tighter rings, or ankle edema. The Nass et al. (2008) study noted transient lower-extremity edema as a common early side effect that typically subsided within the first months (PMID 18981485).

IGF-1 reaches target levels. In the Chapman et al. (1996) study of healthy elderly subjects, 25 mg daily MK-677 raised mean serum IGF-1 from 141 mcg/L at baseline to 265 mcg/L at 4 weeks — restoring levels to the young-adult range (PMID 8954023). This IGF-1 elevation is the primary driver of MK-677's downstream body composition and recovery effects.

Improved recovery. Anecdotally, this is when users first notice reduced soreness after training and faster recovery between sessions. The mechanism is straightforward: elevated GH and IGF-1 enhance protein synthesis and tissue repair.

Joint stiffness. Some users experience mild joint tightness or carpal tunnel-like symptoms from water retention. This is dose-dependent and typically manageable.

Months 1-2: Body Composition Starts Shifting

With IGF-1 now sustained at elevated levels, the downstream anabolic and metabolic effects begin to manifest.

Fat-free mass increases. Svensson et al. (1998) demonstrated that 2 months of MK-677 at 25 mg daily in obese subjects increased GH secretion, fat-free mass, and basal metabolic rate (PMID 9467542). The fat-free mass change at this stage includes both genuine lean tissue accretion and GH-mediated intramuscular water — separating the two requires DEXA or similar imaging.

Muscle fullness. Users commonly report looking "fuller" by weeks 6-8. This is a combination of increased glycogen storage, intramuscular water from GH, and early protein synthesis effects. It is visible in the mirror before it shows on a scale.

Anti-catabolic protection. Murphy et al. (1998) showed MK-677 reversed diet-induced nitrogen wasting — meaning it preserved muscle protein even during caloric restriction (PMID 9467534). For users running MK-677 during a cut, this is the phase where you retain more lean mass than you would without it.

Appetite stabilization. The intense hunger from weeks 1-2 typically mellows by month 2 as ghrelin receptors partially adapt. It does not disappear entirely — MK-677 is a ghrelin mimetic by design — but most users find it manageable.

Bone turnover markers increase. Svensson et al. (1998) measured a 23% increase in bone formation markers (C-terminal propeptide of type I procollagen) and 28% increase in procollagen III peptide after just 2 weeks, with effects continuing through month 2 (PMID 9661080). You will not feel this, but it signals active bone remodeling.

Insulin sensitivity. Fasting glucose may tick upward. This is a documented effect of sustained GH elevation and is dose-dependent and reversible upon discontinuation. Monitor if you have pre-diabetic markers.

Months 3-6: Long-Term Gains and Sustained IGF-1

This is where MK-677's long-duration clinical data becomes uniquely valuable. Most GH peptide trials last 4-8 weeks. MK-677 has 2-year data.

Sustained IGF-1 elevation without desensitization. The Nass et al. (2008) 2-year RCT confirmed that 25 mg daily MK-677 maintained elevated GH and IGF-1 throughout the study period. No significant desensitization occurred at the hormonal level (PMID 18981485).

Progressive fat-free mass gains. The Nass study showed MK-677 recipients continued gaining fat-free mass over 12 months, while the placebo group lost fat-free mass. However — and this is an important caveat — these gains did not translate to measurable strength or functional improvements in the elderly study population.

Bone density. Bone remodeling initiated in months 1-2 begins translating to measurable density changes at 6+ months. Murphy et al. (2001) showed MK-677 combined with alendronate increased femoral neck BMD by 4.2% versus 2.5% with alendronate alone in postmenopausal women (PMID 11238495). Standalone bone density effects from MK-677 require extended use.

Side effect profile stabilizes. Water retention typically normalizes by month 2-3. Appetite remains elevated but manageable. Sleep benefits persist. The main ongoing concern is insulin sensitivity — worth monitoring with periodic fasting glucose checks.

Factors That Affect Your Results

MK-677 gives you elevated GH and IGF-1. What you do with that signal determines your outcomes.

Dose. Clinical trials used 25 mg daily. Community protocols range from 10-25 mg. Lower doses (10 mg) produce measurable GH elevation but with diminished downstream effects. Most users settle at 20-25 mg for optimal results. See the MK-677 Dosing Guide for full protocols.

Timing. Bedtime dosing aligns with natural nocturnal GH pulses and mitigates daytime appetite. This is the standard protocol for a reason — it works with your biology rather than against it.

Training stimulus. The Nass study's lack of strength improvements in elderly subjects likely reflects the absence of a training stimulus. GH and IGF-1 enhance protein synthesis, but without resistance training to create the adaptive signal, the anabolic potential is underutilized. Younger, trained individuals combining MK-677 with structured resistance training are more likely to see functional muscle gains.

Diet. MK-677's appetite stimulation makes caloric surplus easy — potentially too easy. For body recomposition, tracking intake is important. The anti-catabolic data from Murphy et al. suggests MK-677 is particularly useful during caloric deficit for muscle preservation.

Age. Older adults with lower baseline GH/IGF-1 may see more dramatic hormonal changes (Chapman et al. showed IGF-1 nearly doubling in elderly subjects). Younger users with already-adequate GH levels may see more modest relative improvements.

Sleep quality. GH release peaks during deep sleep. MK-677 improves sleep architecture, creating a positive feedback loop — but poor sleep hygiene, alcohol, and late-night screens can blunt this effect.

Results by Use Case

Muscle Growth and Body Recomposition

• Weeks 1-3: Increased appetite, fuller muscles (water/glycogen), no real tissue change
• Weeks 4-8: Early lean mass gains, improved recovery between sessions
• Months 2-6: Progressive body composition improvement, best results with consistent resistance training
• Key factor: Training stimulus is essential — MK-677 provides the hormonal environment, but you have to create the adaptive signal

Recovery and Injury Support

• Week 1: Improved sleep quality accelerates overnight recovery
• Weeks 2-4: Reduced DOMS, faster recovery between training sessions
• Months 1-3: Sustained GH/IGF-1 supports tissue repair processes
• Key factor: MK-677 supports recovery indirectly through GH elevation — it is not a targeted healing peptide like BPC-157

Anti-Aging and GH Restoration

• Week 1: Sleep improvement (often the most immediately appreciated effect)
• Weeks 2-4: IGF-1 restored to young-adult range (documented in Chapman 1996)
• Months 3-12: Progressive improvements in skin quality, recovery capacity, body composition
• Key factor: Longest use-case timeline — benefits accumulate over months, not weeks

Muscle Preservation During Cutting

• Week 1: Anti-catabolic protection begins with first GH elevation
• Weeks 2-8: Nitrogen balance preserved despite caloric deficit (Murphy 1998 data)
• Key factor: Appetite stimulation works against you here — bedtime dosing is critical, and tracking calories is non-negotiable

When to Adjust Your Protocol

Signs it is working (weeks 2-4):

• Increased appetite (confirms ghrelin receptor activation)
• Deeper sleep, easier time falling asleep
• Mild water retention (confirms GH elevation)
• Improved recovery between training sessions

Signs you may need to adjust:

• Excessive water retention or edema lasting beyond week 4 — consider reducing dose to 10-15 mg
• Persistent lethargy beyond week 3 — check blood glucose, consider morning dosing
• No appetite change after 2 weeks — verify product quality and dosing accuracy
• Joint pain or carpal tunnel symptoms — typically dose-dependent, reduce and reassess

When to stop:

• Fasting glucose consistently elevated above your baseline range
• Persistent edema not responding to dose reduction
• Any unusual symptoms — discontinue and consult a healthcare provider

MK-677 clears the system within days due to its approximately 24-hour half-life. Effects reverse within 2-4 weeks of discontinuation, with GH and IGF-1 returning to baseline (confirmed in the Nass 2-year study).

Frequently Asked Questions

How quickly does MK-677 start working?

GH elevation begins within hours of the first dose. Appetite increase and improved sleep are the first noticeable effects, appearing within days 1-5. IGF-1 levels rise measurably within the first week and stabilize by weeks 2-4.

When will I see body composition changes from MK-677?

Visible body composition changes — increased muscle fullness and reduced fat — typically emerge between weeks 6-12. Early changes at 4-8 weeks often include water retention that can mask or mimic lean mass gains.

Why am I gaining weight in the first two weeks?

Early weight gain (2-5 lbs) is almost entirely water retention from GH-mediated sodium and fluid retention, plus increased food intake from appetite stimulation. This is normal and stabilizes by weeks 3-4.

How long should I run MK-677 for full results?

A minimum 8-week cycle is needed for meaningful body composition changes. Clinical data shows progressive benefits through 12 months. Most community protocols run 8-12 weeks with 4 weeks off.

Does MK-677 stop working over time?

GH and IGF-1 elevation persists with continued use — the 2-year Nass study confirmed sustained effects. Some users report subjective effects (sleep, appetite) diminishing after 2-3 months as the body adapts. Cycling 8-12 weeks on/4 weeks off is standard practice.

Related Guides

• MK-677 Dosing Guide — 10-25 mg protocols, timing, cycling details
• MK-677 Benefits — 7 research-backed effects ranked by evidence quality
• MK-677 Peptide Page — Vendor pricing and full compound profile
• Ipamorelin Dosing Guide — Injectable GH peptide alternative
• CJC-1295 + Ipamorelin Stack — Complementary GHRH/GHRP stack
• Calculate Your MK-677 Cycle Cost — Estimate cost for your protocol

References

For educational and research purposes only. This is not medical advice. MK-677 is not FDA-approved for any indication and is sold as a research chemical.